Quorum and Kinetiq Acquisition and Integration: What You Need to Know
On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum. Our combined resources offer the research community the ultimate experience engaging with our institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services.
Feedback from clients about this news has been overwhelmingly positive, and we are eager to share the benefit of Quorum’s One-Touch Collaboration™ fused with Advarra’s Altogether Better suite of clinical research and compliance solutions.
We understand that questions may arise as we bring our industry-leading organizations together. As we proceed through the integration process, we are committed to providing proactive answers and support to our clients. We will strive to be transparent and communicative so that you have the information you need to continue your work with as little interruption as possible.
We’ve assembled this FAQ to address some of the most commonly asked questions about the acquisition of Quorum and Kinetiq. If you don’t see your question addressed here, please contact your Study Coordinator or Study Manager or email Business Development.
Q: Will my primary contact change?
A: Please continue to communicate with your existing primary contacts at Quorum and Kinetiq. We will proactively communicate and coordinate any changes in personnel assignments.
Q: How long do you expect integration will take?
A: We anticipate the integration process will take approximately 6 months. Any changes to policies and procedures that impact you will be communicated to you in advance.
Q: We need to audit Advarra or Advarra Consulting as a new vendor. How should we set this up?
A: There are no changes to the Advarra/Advarra Consulting, Inc. legal entities or standard operating procedures, so clients who have already qualified Advarra as a vendor should not need to re-qualify Advarra as a vendor. Any legacy Quorum/Kinetiq customers who have not yet worked with Advarra and wish to audit Advarra as a new vendor may request to schedule an audit by sending an audit request to Advarra’s Quality Assurance Team.
Q: What will happen to my existing studies?
A: Over the next few weeks, there will be no changes to currently active studies. They will remain with the IRB that originally reviewed the study, and any written IRB correspondence/documentation will be issued from the reviewing IRB. Your current study contacts and timelines will not be affected.
As Quorum and Kinetiq continue the integration process, we will be harmonizing and optimizing our processes, technology platforms, and standards of practice to ensure our combined clients are provided with and have access to the most efficient, customer-focused, and highest quality service provider in the industry.
Q: Do I have to use a different submission form or system?
A: Please continue to use OnQ to submit materials for existing studies and sites overseen by Quorum Review. Over the next few months, new study submissions for initial review will be transitioned to the Advarra Center for IRB Intelligence (CIRBI) Platform. Clients may begin submitting new studies for initial review now via the Advarra CIRBI Platform.
Studies currently managed via the OnQ platform will migrate to the Advarra CIRBI Platform in the coming months. Changes will be communicated and coordinated with you well in advance, and any training needs will be provided on a routine and ongoing basis.
Q: I’ve never used the Advarra CIRBI Platform. How do I get started?
A: Follow these steps to set up a new CIRBI account:
- Click here to register as a new CIRBI user.
- Complete the online registration form and click the “Register” button at the bottom right of the form.
- Advarra will set up your account and send you an automated email with a temporary password. Use the information from that email to login to CIRBI.
- To access brief how-to videos on using CIRBI, login to the platform, then click the “Reference Materials” tab located at the top left.
- Click the hyperlink “Advarra IRB Reference Materials” in the short list of blue hyperlinks and orange folder icons.
- Scroll down to the blue header labeled “CIRBI QuickNotes/Help” and click the hyperlink “CIRBI How-To Video – Account Set-Up.”
Q: What is the impact of the acquisition and name changes to 1572s?
A: The 1572 will not require an update. This is a sponsor form. Clients should email email@example.com with any further questions. Advarra will release a 1572 Note to File regarding the transfer of studies from Quorum’s IRB to Advarra. Clients should file the Note to File and no other assignment is required.
Q: Will the composition of your review boards change?
A: All of the existing review boards for Quorum Review currently remain in place. As integration proceeds, Advarra and Quorum boards will have access to the expertise of each other’s board members, providing even greater resources and expertise for the review of your study.
Q: Will there be any delays to my submissions?
A: There will be no impact or delays to your study submissions. Current processes and review boards will remain in place. All of our integration planning and efforts are focused on making sure the work gets done with the same industry-leading quality and timeframe you have come to expect.
Q: How is Advarra Consulting/Kinetiq ensuring its status as an independent entity?
A: Kinetiq is now part of Advarra Consulting. We will continue to deliver a full suite of Clinical Quality Assurance (CQA), GXP consulting, and Human Research Protection (HRP) consulting services to our customers and Advarra Consulting will maintain a separate legal entity and reporting structure under the Advarra parent company.
Q: How does Advarra Consulting/Kinetiq avoid conflict of interest in serving both CROs and pharma companies?
A: Advarra has a corporate policy for the Avoidance of Conflict of Interest. This policy outlines the separation of data and activities to assure appropriate separation and confidentiality between the activities of the IRB and Advarra Consulting.
Q: Is the acquisition complete?
A: Yes. Advarra’s acquisition of Quorum was completed on February 28, 2019. Both companies will continue to operate on legacy IRB meeting schedules during integration. Advarra anticipates full integration of all operations, IT systems, IRB rosters, consulting engagements, and other service lines by September 1, 2019.
Q: What is Advarra’s legal structure?
A: CS Intermediate Inc. is the parent company to all of Advarra’s entities. The operating company Advarra Inc. is an Ohio corporation with headquarters located at 6940 Columbia Gateway Drive, Suite 110, Columbia, MD 21046.
Q: What is the relationship between all of Advarra’s entities?
A: As a result of the acquisition, Quorum’s operations will be rolled into Advarra, and the combined company will operate as Advarra, Inc. Advarra, Inc. is comprised of the following affiliates and subsidiaries:
- Advarra Consulting, Inc. (wholly owned subsidiary)
- Chesapeake Research Review, LLC (affiliate)
- 0988560 BC Ltd. d/b/a Advarra (affiliate)
- Quorum Review Inc. (affiliate)
Q: What changes have been made to Advarra as a result of the acquisition?
A: There are no legal entity changes to Advarra as a result of the acquisition. Advarra’s standard operating procedures (SOPs) remain unchanged, and the Advarra CIRBI Platform will continue to be utilized as part of our service offerings. Quorum/Kinetiq operations will integrate into Advarra’s operations and IT systems over the next few months, and all agreements will be moved to Advarra in a similar timeframe.
Q: Will Advarra need to update its registration in client vendor portals?
A: Advarra’s payment information will remain unchanged. As study submissions and consulting projects are transferred from Quorum and Kinetiq to Advarra, clients will receive invoices on Advarra letterhead, and we will communicate the Advarra remittance information to those customers along with their invoices. Should we make a change in payment information for any entity, it will be communicated to all customers and vendors via letters that share the new payment information.
Q: Will clients with Advarra contracts have a single point of payment for all invoices (both from Advarra and Quorum?)
A: Currently the long-standing banking information for each entity remains in place. We are in the process of harmonizing our treasury structure, and all updates will be communicated to customers in connection with implementation.
Q: Are clients being updated to a new fee schedule?
A: Advarra will honor negotiated fee schedules for clients who have prices locked under task orders. For negotiated fee schedules under an MSA, Advarra’s Business Development Team will reach out to clients to determine the entity-level fee schedule that will apply to studies submitted to Advarra. Fee schedule requests should be sent to Business Development.
Q: Will there be changes to the method of payment for invoices distributed?
A: There are no changes at this time. Currently the long-standing banking information for each entity remains in place. We are in the process of harmonizing our treasury structure, and all updates will be communicated to customers in connection with implementation.
Q: I was working with Quorum. Do I need a new W-9 for Advarra?
A: Advarra and Quorum are separate entities and maintain separate FEINs. Until banking information is harmonized, payments will be made to the entity noted on each invoice based on who the study is submitted to. W-9 documents for both Quorum and Advarra are available by contacting Advarra’s Accounting Team.
Q: I have an MSA with both Advarra and Quorum. What should I expect?
A: Advarra’s contracts team is actively engaging clients who have MSAs with both Quorum and Advarra to consolidate under one Advarra MSA.
Q: I have an MSA with Quorum; what should I expect?
A: Contracts with Quorum will remain valid; however, Advarra’s Contracts and Proposals Group (CPG) will be reaching out to assign current MSAs from Quorum to Advarra and to indicate the name change/assignment and any necessary amendment. You will receive communication directly from Advarra’s CPG Team. Questions regarding contract status should be sent to CPG.
Q: I have an MSA with Advarra; what should I expect?
A: Contracts with Advarra, Inc. remain valid and will not require any amendment or assignment. Questions regarding contract status should be sent to Advarra’s Contracts and Proposals Group (CPG).
Q: I have an MSA with Kinetiq; what should I expect?
A: As part of the acquisition, Kinetiq services will be offered under Advarra Consulting, Inc. This will not affect the validity of these contracts; however, Advarra’s Contracts and Proposals Group (CPG) will be reaching out to assign current MSAs from Kinetiq to Advarra Consulting, Inc. and to indicate the name change/assignment and any necessary amendment. You will receive communication directly from Advarra’s contracts team. Questions regarding contract status should be sent to CPG.
Q: I have a reliance agreement or global institutional authorization agreement (IAA) with Quorum. What should I expect?
A: We anticipate Quorum’s IRB registration number with OHRP/FDA will be deactivated sometime in Q2. At that time, Advarra will release a 1572 Note to File regarding the transfer of studies from Quorum’s IRB to Advarra. Clients should file the Note to File alongside their IAAs; no other assignment is required.
We recommend that clients with global reliance agreements or IAAs work with Advarra’s Institutions Team to enter into the global agreement under Advarra to ensure a smooth transition of services.
Once the IRB registration update is complete, clients will notice that approval documents and other templates will be under the Advarra name. Until that point, all documents will continue with the entity to whom they were submitted.
Q: My contract includes affiliate language. Who are Advarra’s affiliates?
A: Advarra’s affiliate entities are all legal entities who share the common ownership structure of our parent company CS Intermediate, Inc. Those entities include Advarra, Inc., Quorum Review, Inc., Chesapeake Research Review LLC., 0988560 BC Ltd. (d/b/a Advarra), and Advarra Consulting, Inc.